Download presentation
Presentation is loading. Please wait.
Published byMeghan Sharp Modified over 5 years ago
1
A model for the biological rationale for rechallenge therapy: clonal selection in heterogeneous baseline RAS a wt tumours during anti-EGFR therapy. aAdditional or secondary acquired mechanisms of resistance can also be driven by mutations in the extracellular domain of the EGFR, and other potential biomarkers continue to be investigated. A model for the biological rationale for rechallenge therapy: clonal selection in heterogeneous baseline RASa wt tumours during anti-EGFR therapy. aAdditional or secondary acquired mechanisms of resistance can also be driven by mutations in the extracellular domain of the EGFR, and other potential biomarkers continue to be investigated. EGFR, epidermal growth factor receptor; mut, mutant; wt, wild-type. Richard M Goldberg et al. ESMO Open 2018;3:e000353 Copyright © European Society for Medical Oncology. All rights reserved.
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.